Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-Current Assets: 2010-2024

Historic Non-Current Assets for Iovance Biotherapeutics (IOVA) over the last 10 years, with Dec 2024 value amounting to $453.4 million.

  • Iovance Biotherapeutics' Non-Current Assets was N/A to $475.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $475.9 million, marking a year-over-year change of. This contributed to the annual value of $453.4 million for FY2024, which is 4.04% down from last year.
  • According to the latest figures from FY2024, Iovance Biotherapeutics' Non-Current Assets is $453.4 million, which was down 4.04% from $472.5 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Non-Current Assets ranged from a high of $472.5 million in FY2023 and a low of $453.4 million during FY2024.
  • For the 2-year period, Iovance Biotherapeutics' Non-Current Assets averaged around $463.0 million, with its median value being $463.0 million (2023).
  • Data for Iovance Biotherapeutics' Non-Current Assets shows a maximum YoY declined of 4.04% (in 2024) over the last 5 years.
  • Over the past 2 years, Iovance Biotherapeutics' Non-Current Assets (Yearly) stood at $472.5 million in 2023, then fell by 4.04% to $453.4 million in 2024.